Exactech received FDA 510(k) clearance to market the Equinoxe® Stemless Shoulder, a bone- and canal-sparing implant for total shoulder arthroplasty. Limited launch is underway, with expanded release slated for 2H18.
The device is accompanied by a single instrument tray to support O.R. efficiency, and features a 3D porous structure and bone cage to enhance biologic fixation.
The Equinoxe line, first launched in 2004, includes components for primary, revision, reverse, fracture, resurfacing, etc.
Exactech received FDA 510(k) clearance to market the Equinoxe® Stemless Shoulder, a bone- and canal-sparing implant for total shoulder arthroplasty. Limited launch is underway, with expanded release slated for 2H18.
The device is accompanied by a single instrument tray to support O.R. efficiency, and features a 3D porous structure and bone...
Exactech received FDA 510(k) clearance to market the Equinoxe® Stemless Shoulder, a bone- and canal-sparing implant for total shoulder arthroplasty. Limited launch is underway, with expanded release slated for 2H18.
The device is accompanied by a single instrument tray to support O.R. efficiency, and features a 3D porous structure and bone cage to enhance biologic fixation.
The Equinoxe line, first launched in 2004, includes components for primary, revision, reverse, fracture, resurfacing, etc.
Copy to clipboard 
